Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. PPG

Go back to Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 11c

Xeris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Highlights

August 5, 2021 7:00 AM EDT

Gvoke® prescription volume up 32% versus prior quarter

Gvoke unit sales to wholesalers and other direct customers up 36% versus prior quarter

Gvoke quarterly net sales up 10% to $8.8 million versus prior quarter

Strong cash position of $116 million

FDA approved Gvoke 1mg shelf-life extension to 30 months

EIH program to move forward in early 2022 with a Phase 2 study in broader patient populations

Proposed acquisition of Strongbridge Biopharma plc on track to close early... More